We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
At least one patient has filed a lawsuit against a drug-eluting stent manufacturer due to potential risks he says the firm knew about but failed to divulge to doctors and patients.
German company Altana has completed the sale of its pharmaceutical business to Danish drugmaker Nycomed for approximately $6 billion, Altana announced.
A joint FDA advisory committee recommendation of narrower indications for, and increased warnings on, sanofi-aventis’ antibiotic Ketek has the company taking steps to respond as a competitor may begin grabbing market share.
VaxGen says that HHS has terminated for default the company’s $877.5 million contract to provide 75 million doses of a modern anthrax vaccine for civilian biodefense.
A new congressional report has concluded that the drug industry's increasing investment in R&D is not resulting in sufficient increases in the new drug pipeline and structural changes are necessary to fix a "stagnant" system.
While sales of medical imaging equipment are likely to slow over the next year, new technologies expected to emerge in 2008 should reenergize the market, an analyst says.
Cardinal Health will pay $11 million to settle an investigation by the New York Attorney General’s Office into the purchase and sale of pharmaceutical products on the secondary market, the company announced.
The FDA’s recent warning about serious adverse events involving off-label uses of Genentech’s drug Rituxan is unlikely to have a long-term financial impact on the company, a financial analyst says.
Moving to cut in on the proposed merger between CVS and Caremark Rx, Express Scripts is proposing to acquire all of the remaining shares of Caremark for about $26 billion, the company announced.
A joint FDA advisory committee recommendation of narrower indications for, and increased warnings on, sanofi-aventis’ antibiotic Ketek has the company taking steps to respond as a competitor may begin grabbing market share.